JEPI's share price keeps climbing while its monthly cash payments quietly shrink, and the reason behind that split reveals something most income investors never check before buying a covered-call fund.
Treasury yields near 5% make dividend stocks work harder to justify their risk, yet five companies spanning tobacco, pipelines, telecom, pharma, and net-lease real estate have kept raising their payouts through every…
A 10% yield sounds like it solves the $6,400 monthly target with far less capital, but two of the three tests that expose a yield trap can disqualify a holding before you…
AbbVie (NYSE:ABBV | ABBV Price Prediction) reports third-quarter results before the open on October 30. Shares are up 28.55% year to date, and options pricing implies a roughly 5% move on the…
Rich Duprey When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each betting on newer drugs to fill the gap, but how close each one…
Treasury yields have turned dividend investing into a minefield, but five mega-caps have quietly raised their payouts through every rate spike, recession, and patent cliff of the past four decades. The question…
Johnson and Johnson just posted a quarter where one business charged ahead while another quietly stalled, and which side wins out will determine whether the stock earns its premium valuation over rivals…
Three popular dividend stocks are paying out well above their free cash flow, and the gap between what each one earns and what it sends to shareholders reveals very different risks hiding…
Social Security raises are locked to a government formula, but a growing number of retirees are routing their income strategy around it entirely, and the stocks they are buying span five very…
Two option-income ETFs sell calls against the same index, pay nearly identical yields, and yet one nearly doubled the other's total return over the past year. The way each fund is built…
Johnson & Johnson just posted a quarter that sent shares sliding despite a headline beat, yet analysts keep piling into the bull camp with price targets well above current levels. Here is…
AbbVie's stock has surged nearly 29% this year, but a rising share price compresses the yield even as the dividend keeps growing. Before adding shares for income, consider what the pending Apogee…
Both are Dividend Kings with decades of consecutive raises, but Medtronic and Abbott reward income investors in fundamentally different ways, and choosing the wrong one in retirement could cost you more than…
Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway. The five names on this list have already replaced their fading blockbusters with something…
Two of these five dividend stocks just took a beating in October, and that selloff quietly pushed their yields to levels that make the safer-looking names on the list look stingy by…
